In­vestor suit fu­eled by news ar­ti­cles over failed can­cer drug ends in $24M set­tle­ment

3 years ago
Deals
Law

Io­n­is, As­traZeneca go­ing to FDA with PhI­II da­ta in hand; Glaukos touts dou­ble PhI­II win in eye im­plant

3 years ago
News Briefing

Paci­ra looks to ex­pand use of Ex­par­el for pain re­lief fol­low­ing knee re­place­ment surgery

3 years ago
R&D

Shoot­ing for a heav­i­ly pre-treat­ed niche can­cer mar­ket, Bi­cy­cle re­veals a 'mixed' da­ta cut

3 years ago
R&D

'Con­flicts of in­ter­est': SEC charges Per­cep­tive Ad­vi­sors over SPAC deal­ings, set­tles for $1.5M penal­ty

3 years ago
People
Law

Tiny tran­scrip­tome biotech se­cures Se­ries A to ramp up au­to­mat­ed R&D ef­forts in race to­ward clin­ic

3 years ago
Financing

Af­ter block­ing Grail ac­qui­si­tion, EU leaves Il­lu­mi­na with few good op­tions

3 years ago
Deals
Diagnostics

Fol­low­ing luke­warm launch and lay­offs, Zealand Phar­ma is li­cens­ing out its di­a­betes drug to No­vo Nordisk

3 years ago
Deals

Good Ther­a­peu­tics sells PD-1 IL-2 pro­gram to Roche for $250M and will march on with a sim­i­lar name, but in Latin

3 years ago
Deals
Pharma

Watch out Mod­er­na: John Maraganore, ARCH and Beam are hatch­ing a plat­form play 'to lead the fu­ture of RNA ther­a­pies'

3 years ago
Startups
Cell/Gene Tx

A Rich Hey­man biotech backed by a top Salk sci­en­tist is auc­tioned off for its dwin­dling cash re­serves

3 years ago
Deals

Over $50M in fed­er­al funds are go­ing to Vir­ginia’s phar­ma man­u­fac­tur­ing sec­tor

3 years ago
Financing
Pharma

'Vac­cines are not par­ti­san': White House ramps up de­liv­ery of bi­va­lent boost­ers

3 years ago
Coronavirus

Bay­er agrees to pay $40M to set­tle kick­back, safe­ty claims sparked by whistle­blow­er

3 years ago
Pharma
Law

Boehringer In­gel­heim preps FDA sub­mis­sion with new da­ta in rare pe­di­atric lung dis­ease

3 years ago
R&D
Pharma

Sun Phar­ma en­lists der­ma­tol­ogy HCPs to talk about per­son­al ac­ne ex­pe­ri­ences in new cam­paign

3 years ago
Pharma
Marketing

As­traZeneca ex­pands its block­buster Imfinzi fran­chise with new ap­proval in bil­iary tract can­cer

3 years ago
Pharma
FDA+

For­mer con­tract man­u­fac­tur­er CEO sen­tenced to prison for ship­ping con­t­a­m­i­nat­ed drugs to chil­dren's hos­pi­tals

3 years ago
Pharma
Manufacturing

Mar­ket­ingRx roundup: Pfiz­er boosts sci­ence with pop cul­ture takes on Face­book; BMS, Jazz de­but new SU2C teams

3 years ago
Pharma
Marketing

Noth­ing to laugh about: What hap­pened to hu­mor in phar­ma ad­ver­tis­ing?

3 years ago
Pharma
Marketing

Eye-fo­cused Iver­ic Bio re­ports pos­i­tive PhI­II read­out as shares surge, FDA fil­ing planned

3 years ago
R&D

FDA's out­side ex­perts to re­view GSK, As­traZeneca drugs; Biotech gives very ear­ly pos­i­tive in­di­ca­tions for cell ...

3 years ago
News Briefing

Up­dat­ed: Athi­ra plots an Alzheimer's come­back af­ter scan­dal, PhII fail — and hints at pos­si­ble ac­cel­er­at­ed ...

3 years ago
R&D
FDA+

Covid-19 roundup: CanSi­no’s in­haled vac­cine gets thumbs-up from Chi­nese reg­u­la­tors; Sino­vac gets go-ahead for ...

3 years ago
Coronavirus
First page Previous page 472473474475476477478 Next page Last page
A service from the Financial Times